BNP Paribas Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $197M | Buy |
1,493,813
+97,911
| +7% | +$13M | 0.23% | 85 |
|
|
2025
Q4 | $198M | Buy |
1,395,902
+447,869
| +47% | +$64.9M | 0.23% | 79 |
|
|
2025
Q3 | $133M | Sell |
948,033
-84,263
| -8% | -$11.4M | 0.34% | 54 |
|
|
2025
Q2 | $130M | Sell |
1,032,296
-222,810
| -18% | -$25.6M | 0.32% | 62 |
|
|
2025
Q1 | $139M | Buy |
1,255,106
+310,368
| +33% | +$39.3M | 0.37% | 54 |
|
|
2024
Q4 | $129M | Buy |
944,738
+124,770
| +15% | +$15.4M | 0.32% | 68 |
|
|
2024
Q3 | $94.5M | Buy |
819,968
+37,098
| +5% | +$5.09M | 0.23% | 99 |
|
|
2024
Q2 | $108M | Sell |
782,870
-7,323
| -0.9% | -$1M | 0.28% | 81 |
|
|
2024
Q1 | $109M | Buy |
790,193
+69,600
| +10% | +$9.51M | 0.29% | 77 |
|
|
2023
Q4 | $94.9M | Buy |
720,593
+42,263
| +6% | +$4.86M | 0.26% | 94 |
|
|
2023
Q3 | $76.3M | Buy |
678,330
+21,308
| +3% | +$2.24M | 0.23% | 107 |
|
|
2023
Q2 | $62M | Buy |
657,022
+44,368
| +7% | +$4.34M | 0.19% | 130 |
|
|
2023
Q1 | $62M | Buy |
612,654
+61,297
| +11% | +$6.38M | 0.21% | 114 |
|
|
2022
Q4 | $65.9M | Buy |
551,357
+17,851
| +3% | +$2.09M | 0.24% | 109 |
|
|
2022
Q3 | $56.7M | Buy |
533,506
+85,689
| +19% | +$8.69M | 0.22% | 106 |
|
|
2022
Q2 | $43.7M | Buy |
447,817
+88,840
| +25% | +$8.2M | 0.17% | 143 |
|
|
2022
Q1 | $33.7M | Sell |
358,977
-13,615
| -4% | -$1.15M | 0.12% | 210 |
|
|
2021
Q4 | $31.7M | Sell |
372,592
-19,158
| -5% | -$1.76M | 0.11% | 235 |
|
|
2021
Q3 | $37.6M | Sell |
391,750
-1,192
| -0.3% | -$113K | 0.14% | 184 |
|
|
2021
Q2 | $38.2M | Buy |
392,942
+69,482
| +21% | +$6.66M | 0.14% | 190 |
|
|
2021
Q1 | $31.5M | Buy |
323,460
+65,431
| +25% | +$6.86M | 0.13% | 186 |
|
|
2020
Q4 | $24.7M | Sell |
258,029
-5,867
| -2% | -$567K | 0.11% | 215 |
|
|
2020
Q3 | $25.4M | Buy |
263,896
+42,543
| +19% | +$4.92M | 0.14% | 176 |
|
|
2020
Q2 | $27M | Sell |
221,353
-14,531
| -6% | -$1.61M | 0.18% | 151 |
|
|
2020
Q1 | $20.4M | Buy |
235,884
+32,994
| +16% | +$3.23M | 0.17% | 160 |
|
|
2019
Q4 | $21.8M | Sell |
202,890
-95,184
| -32% | -$9.97M | 0.15% | 189 |
|
|
2019
Q3 | $26.9M | Sell |
298,074
-106,738
| -26% | -$9.97M | 0.21% | 136 |
|
|
2019
Q2 | $34.2M | Buy |
404,812
+37,933
| +10% | +$3.11M | 0.28% | 90 |
|
|
2019
Q1 | $32.3M | Buy |
366,879
+186,150
| +103% | +$15.6M | 0.27% | 89 |
|
|
2018
Q4 | $12.4M | Sell |
180,729
-11,723
| -6% | -$1.12M | 0.11% | 248 |
|
|
2018
Q3 | $23.7M | Sell |
192,452
-53,695
| -22% | -$6.09M | 0.18% | 155 |
|
|
2018
Q2 | $24.2M | Buy |
246,147
+136,401
| +124% | +$12.2M | 0.2% | 133 |
|
|
2018
Q1 | $9.1M | Sell |
109,746
-141,453
| -56% | -$11.9M | 0.08% | 343 |
|
|
2017
Q4 | $19.5M | Sell |
251,199
-271,602
| -52% | -$18.5M | 0.17% | 161 |
|
|
2017
Q3 | $32M | Buy |
522,801
+133,175
| +34% | +$7.03M | 0.27% | 80 |
|
|
2017
Q2 | $17.9M | Buy |
389,626
+180,437
| +86% | +$8.75M | 0.16% | 165 |
|
|
2017
Q1 | $9.06M | Buy |
209,189
+23,782
| +13% | +$1.02M | 0.08% | 336 |
|
|
2016
Q4 | $7.17M | Buy |
185,407
+14,615
| +9% | +$662K | 0.07% | 385 |
|
|
2016
Q3 | $8.65M | Sell |
170,792
-12,471
| -7% | -$621K | 0.07% | 365 |
|
|
2016
Q2 | $8.33M | Buy |
183,263
+124,022
| +209% | +$5.71M | 0.07% | 361 |
|
|
2016
Q1 | $2.34M | Buy |
+59,241
| New | +$2.35M | 0.02% | 645 |
|
|
2015
Q2 | – | Sell |
-17,231
| Closed | -$684K | – | 1060 |
|
|
2015
Q1 | $684K | Sell |
17,231
-1,632
| -9% | -$58.4K | 0.01% | 896 |
|
|
2014
Q4 | $421K | Buy |
+18,863
| New | +$357K | ﹤0.01% | 866 |
|
|
2013
Q4 | – | Sell |
-184,125
| Closed | -$2.08M | – | 840 |
|
|
2013
Q3 | $2.08M | Sell |
184,125
-56,452
| -23% | -$776K | 0.02% | 590 |
|
|
2013
Q2 | $3.22M | Buy |
+240,577
| New | +$2.96M | 0.02% | 525 |
|
Other funds holding NBIX
VPM
VCM
BNP Paribas Asset Management's NBIX Position: Q1 2026 in Review
BNP Paribas Asset Management increased its Neurocrine Biosciences (NBIX) stake by 7% in Q1 2026, buying an estimated $13M and bringing the position to 1,493,813 shares worth $197M. The position accounts for 0.23% of the portfolio, ranked #85.
BNP Paribas Asset Management first reported a position in NBIX in Q2 2013 and has held it in 45 quarters since. The position peaked at $198M in Q4 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- BNP Paribas Asset Management held 1,493,813 shares of Neurocrine Biosciences worth $197M as of Q1 2026.
- BNP Paribas Asset Management bought 97,911 Neurocrine Biosciences shares in Q1 2026, an estimated $13M.
- Neurocrine Biosciences made up 0.23% of BNP Paribas Asset Management's portfolio in Q1 2026, its #85 holding.
- BNP Paribas Asset Management first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 45 quarters since.
- BNP Paribas Asset Management's Neurocrine Biosciences position peaked at $198M in Q4 2025.
- 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.